Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma
L Khoja, C Maurice, MA Chappell, L MacMillan… - Cancer immunology …, 2016 - AACR
Anti–PD-1 inhibitors have significant activity in metastatic melanoma. Responses often occur
early and may be sustained. The optimal duration of treatment with these agents is
unknown. Here, we report the case of a 51-year-old woman treated with pembrolizumab, as
part of the Keynote-001 trial, as first-line treatment for metastatic disease. She experienced a
complete response after 13.8 months of treatment with no adverse events. One month after
the last drug infusion and 18 months from starting treatment, the patient presented with …
early and may be sustained. The optimal duration of treatment with these agents is
unknown. Here, we report the case of a 51-year-old woman treated with pembrolizumab, as
part of the Keynote-001 trial, as first-line treatment for metastatic disease. She experienced a
complete response after 13.8 months of treatment with no adverse events. One month after
the last drug infusion and 18 months from starting treatment, the patient presented with …
以上显示的是最相近的搜索结果。 查看全部搜索结果